About

Novan, Inc. is a medical dermatology company primarily focused on researching, developing, and commercializing innovative therapeutic products for skin diseases. Our goal is to deliver safe and efficacious therapies to patients, including developing product candidates where there are unmet medical needs. We are developing berdazimer gel, 10.3% (SB206) as a topical prescription gel for the treatment of viral skin infections, with current emphasis on molluscum contagiosum.

 

Novan completed the acquisition of EPI Health in early 2022. EPI Health equips the company with a robust commercial infrastructure across sales, marketing, and communications, as well as fully dedicated market access and pharmacy relation teams. Following the acquisition, the company promotes products for plaque psoriasis, rosacea and acne. Novan also has a pipeline of potential product candidates using our proprietary nitric oxide-based technology platform, NITRICIL™, to generate new treatments for multiple indications.

 

NOVAN PRIDE UNDERPINS OUR EFFORTS

 

Performance

We are empowered to take ownership while being accountable in providing timely and compliant deliverables

Respectful

We are collaborative and foster open dialogue to create trust while assuming positive intent

Innovative

We are responsive to our science, our customers, our patients, and we are open to new perspectives and ideas in all that we do

Dynamic

We are transparent in communicating change, and we are laser-focused on patients’ needs, and the well-being of our employees and our business

Engaged

We are committed and dedicated to working together as a team to improve patients’ lives and celebrate our successes along the way

Novan, Inc. is a medical dermatology company primarily focused on researching, developing, and commercializing innovative therapeutic products for skin diseases. Our goal is to deliver safe and efficacious therapies to patients, including developing product candidates where there are unmet medical needs. We are developing berdazimer gel, 10.3% (SB206) as a topical prescription gel for the treatment of viral skin infections, with current emphasis on molluscum contagiosum.

Novan completed the acquisition of EPI Health in early 2022. EPI Health equips the company with a robust commercial infrastructure across sales, marketing, and communications, as well as fully dedicated market access and pharmacy relation teams. Following the acquisition, the company promotes products for plaque psoriasis, rosacea and acne. Novan also has a pipeline of potential product candidates using our proprietary nitric oxide-based technology platform, NITRICIL™, to generate new treatments for multiple indications.

 

NOVAN PRIDE UNDERPINS OUR EFFORTS

 

Performance

We are empowered to take ownership and provide quality outcomes and timely deliverables

Respectful

We are collaborative, we participate in active listening and support an open dialogue

Innovative

We are responsive to our science, and are open to new perspectives and ideas in all that we do

Dynamic

We are intentional in managing change, and we are responsive to our business, employees, and patient needs

Engaged

We are committed and dedicated to working together to improve patients’ lives

Management Team

Our Science

Our Pipeline

Sign Up For Alerts